Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study
Infection Control & Hospital Epidemiology · 2024
DOI: 10.1017/ice.2024.117 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Infection Control & Hospital Epidemiology, 2024. Verfasst von Sarah E Moore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare rates of Clostridioides difficile infection (CDI) recurrence following initial occurrence treated with tapered enteral vancomycin compared to standard vancomycin.
Design
Retrospective cohort study.
Setting
Community health system. Patients: Adults ≥18 years of age hospitalized with positive C. difficile polymerase chain reaction or toxin enzyme immunoassay who were prescribed either standard 10–14 days of enteral vancomycin four times daily or a 12-week tapered vancomycin regimen.
Methods
Retrospective propensity score pair matched cohort study. Groups were matched based on age < or ≥ 65 years and receipt of non- C. difficile antibiotics during hospitalization or within 6 months post-discharge. Recurrence rates were analyzed via logistic regression conditioned on matched pairs and reported as conditional odds ratios. The primary outcome was recurrence rates compared between standard vancomycin versus tapered vancomycin for treatment of initial CDI.
Results
The CDI recurrence rate at 6 months was 5.3% (4/75) in the taper cohort versus 28% (21/75) in the standard vancomycin cohort. The median time to CDI recurrence was 115 days versus 20 days in the taper and standard vancomycin cohorts, respectively. When adjusted for matching, patients in the taper arm were less likely to experience CDI recurrence at 6 months when compared to standard vancomycin (cOR = 0.19, 95% CI 0.07–0.56, p < 0.002).
Conclusions
Larger prospective trials are needed to elucidate the clinical utility of tapered oral vancomycin as a treatment option to achieve sustained clinical cure in first occurrences of CDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA.
- Norton Healthcare, Department of Pharmacy, Louisville, KY, USA.
- Baptist Health Hardin, Department of Pharmacy, Elizabethtown, KY, USA.
ORCID-Profile: Sarah E Moore, Matthew Song, Elena A Swingler, Thomas Chandler, Martin T Brenneman, Ashley M Wilde
Zitieren
APA
Moore, S. E., Song, M., Swingler, E. A., Furmanek, S., Chandler, T., Smith, D., Brenneman, M. T., & Wilde, A. M. (2024). Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2024.117
Vancouver
Moore SE, Song M, Swingler EA, Furmanek S, Chandler T, Smith D, et al. Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study. Infection Control & Hospital Epidemiology. 2024. doi:10.1017/ice.2024.117
BibTeX
@article{Moore2024,
author = {Moore, Sarah E and Song, Matthew and Swingler, Elena A and Furmanek, Stephen and Chandler, Thomas and Smith, Dakota and Brenneman, Martin T and Wilde, Ashley M},
title = {Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study},
journal = {Infection Control & Hospital Epidemiology},
year = {2024},
doi = {10.1017/ice.2024.117}
}
EUVIMED